Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. A key difference between compounded semaglutide and Ozempic is the lack of FDA approval for compounded semaglutide.

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

PharmaZee has developed a GLP-1 weight loss program ... How much weight can I lose with Semaglutide? Depending on individual factors, patients can lose between 10% and 15% of their body weight ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...